MedTrace Logo

PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide

NCT00744224 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2010-01-13

No results posted yet for this study

Summary

The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.

Conditions

  • Glucocorticoid-induced Glucometabolic Abnormalities
  • Glucocorticoid-induced Beta-cell Dysfunction

Interventions

DRUG

Placebo

Single dose of placebo with saline infusion

DRUG

Prednisolone

Single dose of 80 mg prednisolone with saline infusion

DRUG

Prednisolone and Exenatide

Prednisolone 80 mg single dose Exenatide infusion 20 mg/min

Sponsors & Collaborators

  • National Research Council, Institute of Biomedical Engineering

    collaborator UNKNOWN

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Michaela Diamant, MD PhD · Amsterdam UMC, location VUmc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00744224 on ClinicalTrials.gov